Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE RANKIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1922027853
CMS profile
132925
Location
DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$30.36

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $30.36 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Bayer HealthCare Pharmaceuticals Inc. $19.27 1
PFIZER INC. $11.09 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE RANKIN

NPI 1922027853 · CMS profile ID 132925

Allopathic & Osteopathic Physicians / Family Medicine

DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922027853?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922027853?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922027853?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1922027853?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $30.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $11.0909/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949339485 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.2708/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929935687 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,373.98 97
PY2020 $739.07 44
PY2021 $406.88 25
PY2022 $30.36 2
PY2023 $3,057.34 11
PY2024 $1,612.22 12
PY2025 $249.99 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,755.45 1
PY2025 Principal investigator $4,230,288.19 209
PY2024 Recipient $1,330.16 13
PY2024 Principal investigator $3,187,354.20 327
PY2023 Recipient $893.27 4
PY2023 Principal investigator $6,323,793.75 2,767
PY2022 Recipient $462.00 2
PY2022 Principal investigator $6,941,300.42 589
PY2021 Recipient $15.00 1
PY2021 Principal investigator $10,036,876.19 348
PY2020 Recipient $10,602.17 4
PY2020 Principal investigator $3,545,507.10 644
PY2019 Principal investigator $2,410,610.06 875

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

340 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $241.31 12/31/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1155804024
Principal investigator 1 Merck Sharp & Dohme LLC $9,705.84 12/31/2024 Non-covered Recipient Entity
Accel Research Sites-DeLand Clinical Research Unit
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 1136438947
Principal investigator 1 ModernaTX, Inc. $303.75 12/30/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150854
Principal investigator 1 ModernaTX, Inc. $13,294.40 12/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150852
Principal investigator 1 SANOFI PASTEUR INC. $6,600.00 12/23/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128700680
Principal investigator 1 GlaxoSmithKline, LLC. $3,897.81 12/19/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1156003211
Principal investigator 1 Novavax Inc $9,529.17 12/19/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374170
Principal investigator 1 SANOFI PASTEUR INC. $2,400.00 12/19/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700678
Principal investigator 1 Janssen Research & Development, LLC $1,076.00 12/18/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956175
Principal investigator 1 Janssen Research & Development, LLC $3,957.00 12/16/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956143
Principal investigator 1 Janssen Research & Development, LLC $2,628.00 12/16/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956185
Principal investigator 1 SANOFI PASTEUR INC. $3,677.28 12/06/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128700664
Principal investigator 1 ABBVIE INC. $8,500.00 12/05/2024 Non-covered Recipient Entity
UNIV CLINICAL RESEARCH-DELAND LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1100758833
Principal investigator 1 ModernaTX, Inc. $68.30 11/29/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147150848
Principal investigator 1 ModernaTX, Inc. $1,461.51 11/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150834
Principal investigator 1 ModernaTX, Inc. $164,640.30 11/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147150838
Principal investigator 1 ModernaTX, Inc. $2,842.00 11/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150842
Principal investigator 1 Janssen Research & Development, LLC $4,594.00 11/21/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956133
Principal investigator 1 Janssen Research & Development, LLC $4,601.00 11/20/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956151
Principal investigator 1 ModernaTX, Inc. $12,100.00 11/20/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147150836
Principal investigator 1 ModernaTX, Inc. $81.96 11/19/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147150846
Principal investigator 1 ModernaTX, Inc. $24,157.00 11/18/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150840
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530902
Principal investigator 1 GlaxoSmithKline, LLC. $11,000.00 11/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1127530904
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1127530922
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 11/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1127530924
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 11/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1127530990
Principal investigator 1 ModernaTX, Inc. $81.96 11/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147150844
Principal investigator 1 ModernaTX, Inc. $1,500.00 11/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150654
Principal investigator 1 ModernaTX, Inc. $1,575.00 11/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150656
Principal investigator 1 ModernaTX, Inc. $600.00 11/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150658
Principal investigator 1 ModernaTX, Inc. $1,775.00 11/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150660
Principal investigator 1 ModernaTX, Inc. $4,603.50 11/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150652
Principal investigator 1 SANOFI PASTEUR INC. $300.00 11/06/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700666
Principal investigator 1 SANOFI PASTEUR INC. $63.45 11/06/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700668
Principal investigator 1 SANOFI PASTEUR INC. $35.25 11/06/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700670
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $20,107.66 11/01/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITE DELAND CLINICAL RESEARCH UNIT
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1095480872
Principal investigator 1 Novo Nordisk AS $1,213.87 10/31/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096647009
Principal investigator 1 Janssen Research & Development, LLC $12,099.00 10/23/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956095
Principal investigator 1 ModernaTX, Inc. $350.00 10/23/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150638
Principal investigator 1 ModernaTX, Inc. $10,566.33 10/23/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150640
Principal investigator 1 ModernaTX, Inc. $204.90 10/23/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147150830
Principal investigator 1 UCB SA $1,431.49 10/18/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES NETWORK - DELAND CLINICAL RESEARCH UNIT
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1153201982
Principal investigator 1 GlaxoSmithKline, LLC. $780.00 10/17/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530916
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 10/17/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530992
Principal investigator 1 ModernaTX, Inc. $148.50 10/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150588
Principal investigator 1 Janssen Research & Development, LLC $6,442.00 10/15/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956075
Principal investigator 1 SANOFI PASTEUR INC. $450.00 10/15/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700674
Principal investigator 1 SANOFI PASTEUR INC. $324.30 10/15/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128700676
Principal investigator 1 ModernaTX, Inc. $23.00 10/11/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150582
Principal investigator 1 ModernaTX, Inc. $23.00 10/09/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150584
Principal investigator 1 Novavax Inc $1,750.00 10/04/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374707
Principal investigator 1 ModernaTX, Inc. $890.02 10/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150826
Principal investigator 1 ModernaTX, Inc. $78.40 10/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150828
Principal investigator 1 ModernaTX, Inc. $46.00 10/02/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150586
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $20,205.45 10/01/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITE DELAND CLINICAL RESEARCH UNIT
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1095480870
Principal investigator 1 ModernaTX, Inc. $169.00 09/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150818
Principal investigator 1 ModernaTX, Inc. $399.12 09/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147150820
Principal investigator 1 ModernaTX, Inc. $16,076.61 09/25/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150810
Principal investigator 1 ModernaTX, Inc. $590.34 09/23/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150808
Principal investigator 1 ModernaTX, Inc. $2,390.00 09/23/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150816
Principal investigator 1 Novavax Inc $4,000.00 09/19/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374168
Principal investigator 1 ModernaTX, Inc. $5,011.74 09/18/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150806
Principal investigator 1 ModernaTX, Inc. $23,433.20 09/18/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150814
Principal investigator 1 Janssen Research & Development, LLC $6,664.00 09/12/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956087
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/11/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150804
Principal investigator 1 ModernaTX, Inc. $2,553.23 09/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150568
Principal investigator 1 ModernaTX, Inc. $400.00 09/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150570
Principal investigator 1 ModernaTX, Inc. $1,575.00 09/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150574
Principal investigator 1 ModernaTX, Inc. $600.00 09/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150576
Principal investigator 1 ModernaTX, Inc. $5,400.00 09/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150578
Principal investigator 1 ModernaTX, Inc. $1,750.00 09/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150580
Principal investigator 1 ModernaTX, Inc. $2,250.00 09/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150566
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150572
Principal investigator 1 ModernaTX, Inc. $114,507.07 09/02/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150802
Principal investigator 1 ModernaTX, Inc. $169.00 08/30/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150800
Principal investigator 1 ModernaTX, Inc. $11,420.60 08/28/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150798
Principal investigator 1 ModernaTX, Inc. $36,828.00 08/22/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150796
Principal investigator 1 Novo Nordisk AS $3,000.00 08/21/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9535-4984 No dispute reported 06/30/2026 1096628472
Principal investigator 1 Novo Nordisk AS $2,459.34 08/21/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096642181
Principal investigator 1 Janssen Research & Development, LLC $3,592.00 08/19/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956147
Principal investigator 1 ModernaTX, Inc. $1,053.36 08/14/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150794
Principal investigator 1 Janssen Research & Development, LLC $1,556.00 08/13/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956161
Principal investigator 1 Janssen Research & Development, LLC $3,875.00 08/13/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956181
Principal investigator 1 ModernaTX, Inc. $891.00 08/09/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150564
Principal investigator 1 ModernaTX, Inc. $8,646.00 08/07/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150792
Principal investigator 1 Janssen Research & Development, LLC $120.00 08/06/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956085
Principal investigator 1 Janssen Research & Development, LLC $3,250.00 08/05/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956093
Principal investigator 1 GlaxoSmithKline, LLC. $402.14 08/02/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127530908
Principal investigator 1 Novavax Inc $1,781.25 08/02/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374705
Principal investigator 1 ModernaTX, Inc. $53,296.29 07/31/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150698
Principal investigator 1 Janssen Research & Development, LLC $5,548.00 07/29/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956141
Principal investigator 1 Janssen Research & Development, LLC $7,454.00 07/26/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956109
Principal investigator 1 Novavax Inc $1,712.50 07/25/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374166
Principal investigator 1 Novavax Inc $50.00 07/25/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377435
Principal investigator 1 Novo Nordisk AS $15.06 07/25/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096624035
Principal investigator 1 Novo Nordisk AS $15.06 07/25/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096666455
Principal investigator 1 Novo Nordisk AS $15.06 07/25/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096669978
Principal investigator 1 Novo Nordisk AS $15.06 07/25/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096695971
Principal investigator 1 Novo Nordisk AS $1,658.47 07/22/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096668349
Principal investigator 1 Janssen Research & Development, LLC $944.00 07/18/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956121
Principal investigator 1 ModernaTX, Inc. $9,806.28 07/18/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150696
Principal investigator 1 ModernaTX, Inc. $3,289.52 07/17/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150694
Principal investigator 1 ModernaTX, Inc. $31,974.40 07/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150692
Principal investigator 1 Janssen Research & Development, LLC $1,394.00 07/12/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956149
Principal investigator 1 ModernaTX, Inc. $65,641.35 07/11/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150690
Principal investigator 1 ModernaTX, Inc. $930.00 07/11/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150704
Principal investigator 1 ModernaTX, Inc. $31,012.95 07/05/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150688
Principal investigator 1 ModernaTX, Inc. $1,104.60 07/04/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150702
Principal investigator 1 ModernaTX, Inc. $108,720.08 07/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150552
Principal investigator 1 ModernaTX, Inc. $17,906.54 07/01/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150550
Principal investigator 1 Janssen Research & Development, LLC $406.00 06/28/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956103
Principal investigator 1 Janssen Research & Development, LLC $78.00 06/28/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956165
Principal investigator 1 ModernaTX, Inc. $6,338.25 06/28/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150784
Principal investigator 1 SANOFI PASTEUR INC. $18,956.08 06/28/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128701252
Principal investigator 1 ModernaTX, Inc. $2,500.00 06/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150778
Principal investigator 1 ModernaTX, Inc. $47,362.00 06/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150790
Principal investigator 1 Janssen Research & Development, LLC $4,096.00 06/26/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956137
Principal investigator 1 Averitas Pharma Inc. $4,500.00 06/25/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347997
Principal investigator 1 GlaxoSmithKline, LLC. $417.00 06/25/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530984
Principal investigator 1 SANOFI PASTEUR INC. $500.00 06/21/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128701254
Principal investigator 1 Boehringer Ingelheim International GmbH $9,470.00 06/20/2024 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1101069861
Principal investigator 1 Novavax Inc $41,736.32 06/20/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374162
Principal investigator 1 SANOFI PASTEUR INC. $549.90 06/20/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128701256
Principal investigator 1 SANOFI PASTEUR INC. $204,629.91 06/20/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128701258
Principal investigator 1 SANOFI PASTEUR INC. $916.28 06/20/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128701260
Principal investigator 1 Janssen Research & Development, LLC $1,525.00 06/19/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956173
Principal investigator 1 SANOFI PASTEUR INC. $24,094.08 06/19/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128701262
Principal investigator 1 SANOFI PASTEUR INC. $600.00 06/18/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128701264
Principal investigator 1 Janssen Research & Development, LLC $82.00 06/17/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956111
Principal investigator 1 Janssen Research & Development, LLC $13,292.00 06/14/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956145
Principal investigator 1 IBSA Institut Biochimique SA $1,300.00 06/12/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH- DELAND, LLC
18US-FHp04/A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries No dispute reported 06/30/2026 1142342123
Principal investigator 1 ModernaTX, Inc. $875.96 06/12/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150776
Principal investigator 1 ModernaTX, Inc. $314.00 06/12/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150788
Principal investigator 1 GlaxoSmithKline, LLC. $562.30 06/07/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127530914
Principal investigator 1 ModernaTX, Inc. $3,712.50 06/07/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150542
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150782
Principal investigator 1 ModernaTX, Inc. $500.00 06/05/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150780
Principal investigator 1 Janssen Research & Development, LLC $6,450.00 06/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1078996033
Principal investigator 1 ModernaTX, Inc. $23.00 06/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150530
Principal investigator 1 ModernaTX, Inc. $230.00 06/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150536
Principal investigator 1 ModernaTX, Inc. $100.50 05/31/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150760
Principal investigator 1 Novo Nordisk AS $527.08 05/31/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096691986
Principal investigator 1 GlaxoSmithKline, LLC. $4,618.58 05/30/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530910
Principal investigator 1 Novavax Inc $400.00 05/30/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376889
Principal investigator 1 ModernaTX, Inc. $23.00 05/29/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150510
Principal investigator 1 ModernaTX, Inc. $500.00 05/29/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150512
Principal investigator 1 ModernaTX, Inc. $770.00 05/29/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150514
Principal investigator 1 SANOFI PASTEUR INC. $3,887.37 05/29/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128701232
Principal investigator 1 SANOFI PASTEUR INC. $431.46 05/29/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128701242
Principal investigator 1 SANOFI PASTEUR INC. $18,846.11 05/29/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128701244
Principal investigator 1 ModernaTX, Inc. $500.00 05/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150764
Principal investigator 1 ModernaTX, Inc. $44,501.80 05/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150774
Principal investigator 1 Janssen Research & Development, LLC $800.00 05/24/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956107
Principal investigator 1 SANOFI PASTEUR INC. $2,029.70 05/23/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128701246
Principal investigator 1 Janssen Research & Development, LLC $3,743.00 05/22/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956115
Principal investigator 1 SANOFI PASTEUR INC. $2,000.00 05/22/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128701228
Principal investigator 1 SANOFI PASTEUR INC. $7,735.26 05/22/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128701248
Principal investigator 1 Janssen Research & Development, LLC $3,205.00 05/21/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956177
Principal investigator 1 Janssen Research & Development, LLC $100.00 05/20/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956135
Principal investigator 1 Janssen Research & Development, LLC $550.00 05/17/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956179
Principal investigator 1 ModernaTX, Inc. $67.50 05/17/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147150522
Principal investigator 1 GlaxoSmithKline, LLC. $661.04 05/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127526652
Principal investigator 1 GlaxoSmithKline, LLC. $110.17 05/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127530988
Principal investigator 1 Janssen Research & Development, LLC $25.00 05/14/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956113
Principal investigator 1 Novo Nordisk AS $6.67 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096625431
Principal investigator 1 Novo Nordisk AS $6.67 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096628508
Principal investigator 1 Novo Nordisk AS $12.99 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096630546
Principal investigator 1 Novo Nordisk AS $12.99 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096644329
Principal investigator 1 Novo Nordisk AS $6.67 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096647447
Principal investigator 1 Novo Nordisk AS $6.67 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096653065
Principal investigator 1 Novo Nordisk AS $6.67 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096667065
Principal investigator 1 Novo Nordisk AS $6.67 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096668239
Principal investigator 1 Novo Nordisk AS $12.99 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096699231
Principal investigator 1 Novo Nordisk AS $12.99 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096700308
Principal investigator 1 Novo Nordisk AS $12.99 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096704250
Principal investigator 1 Novo Nordisk AS $12.99 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096705477
Principal investigator 1 Novo Nordisk AS $12.99 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096706964
Principal investigator 1 Novo Nordisk AS $6.67 05/13/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096712442
Principal investigator 1 Janssen Research & Development, LLC $1,995.00 05/10/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956117
Principal investigator 1 ModernaTX, Inc. $4,478.20 05/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150772
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150762
Principal investigator 1 Novavax Inc $1,419.53 05/02/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374703
Principal investigator 1 Novavax Inc $2,205.00 04/30/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123375745
Principal investigator 1 Novo Nordisk AS $1,573.02 04/30/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096692086
Principal investigator 1 GlaxoSmithKline, LLC. $381.22 04/26/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127526648
Principal investigator 1 Janssen Research & Development, LLC $4,760.00 04/26/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956187
Principal investigator 1 GlaxoSmithKline, LLC. $9,184.09 04/24/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530928
Principal investigator 1 SANOFI PASTEUR INC. $3,867.63 04/24/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128701226
Principal investigator 1 GlaxoSmithKline, LLC. $57.70 04/19/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127526660
Principal investigator 1 Janssen Research & Development, LLC $452.00 04/18/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956131
Principal investigator 1 SANOFI PASTEUR INC. $31,100.00 04/18/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128701230
Principal investigator 1 Janssen Research & Development, LLC $8,375.00 04/17/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956163
Principal investigator 1 ModernaTX, Inc. $148.50 04/17/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147150508
Principal investigator 1 Averitas Pharma Inc. $1,700.00 04/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347438
Principal investigator 1 Averitas Pharma Inc. $512.00 04/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347453
Principal investigator 1 Averitas Pharma Inc. $4,000.00 04/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347460
Principal investigator 1 Averitas Pharma Inc. $1,500.00 04/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1123347468
Principal investigator 1 Novavax Inc $11,368.00 04/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123374164
Principal investigator 1 SANOFI PASTEUR INC. $1,200.00 04/15/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128701234
Principal investigator 1 SANOFI PASTEUR INC. $600.00 04/15/2024 Non-covered Recipient Entity
University Clinical Research Dela LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128701236
Principal investigator 1 Novavax Inc $2,951.78 04/11/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374701
Principal investigator 1 ModernaTX, Inc. $18,255.07 04/10/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150498
Principal investigator 1 ModernaTX, Inc. $11,300.40 04/10/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150752
Principal investigator 1 Janssen Research & Development, LLC $9,470.00 04/08/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956083
Principal investigator 1 Novavax Inc $250.00 04/04/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375217
Principal investigator 1 GlaxoSmithKline, LLC. $2,652.00 04/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127526662
Principal investigator 1 GlaxoSmithKline, LLC. $347.50 04/02/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530906
Principal investigator 1 GlaxoSmithKline, LLC. $486.50 04/02/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530912
Principal investigator 1 GlaxoSmithKline, LLC. $1,447.99 04/01/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127530994
Principal investigator 1 ModernaTX, Inc. $1,300.00 03/28/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150732
Principal investigator 1 ModernaTX, Inc. $4,002.60 03/28/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150746
Principal investigator 1 Novavax Inc $800.00 03/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374160
Principal investigator 1 Novavax Inc $75.00 03/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377433
Principal investigator 1 Novo Nordisk AS $527.08 03/27/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096658162
Principal investigator 1 Janssen Research & Development, LLC $9,135.00 03/25/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956101
Principal investigator 1 GlaxoSmithKline, LLC. $9,184.09 03/24/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526654
Principal investigator 1 GlaxoSmithKline, LLC. $450.00 03/24/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530986
Principal investigator 1 ModernaTX, Inc. $12,163.80 03/21/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150730
Principal investigator 1 ModernaTX, Inc. $13,890.96 03/21/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150738
Principal investigator 1 ModernaTX, Inc. $65,307.20 03/21/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150744
Principal investigator 1 Janssen Research & Development, LLC $1,180.00 03/20/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956097
Principal investigator 1 UCB SA $550.00 03/20/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) No dispute reported 06/30/2026 1153201128
Principal investigator 1 SANOFI PASTEUR INC. $4,059.40 03/18/2024 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700250
Principal investigator 1 Janssen Research & Development, LLC $25.00 03/14/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956079
Principal investigator 1 SANOFI PASTEUR INC. $1,184.40 03/14/2024 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700248
Principal investigator 1 ModernaTX, Inc. $2,250.00 03/13/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150476
Principal investigator 1 ModernaTX, Inc. $4,810.58 03/13/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147150484
Principal investigator 1 ModernaTX, Inc. $275.56 03/13/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147150486
Principal investigator 1 ModernaTX, Inc. $568,031.55 03/13/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147150488
Principal investigator 1 ModernaTX, Inc. $1,200.00 03/13/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147150490
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/13/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147150492
Principal investigator 1 ModernaTX, Inc. $10,500.00 03/13/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1147150494
Principal investigator 1 Novavax Inc $100.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375743
Principal investigator 1 Novavax Inc $400.00 03/07/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377431
Principal investigator 1 GlaxoSmithKline, LLC. $340.44 03/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127530920
Principal investigator 1 ModernaTX, Inc. $450.00 03/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150474
Principal investigator 1 ModernaTX, Inc. $3,041.22 03/06/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150728
Principal investigator 1 Janssen Research & Development, LLC $13,347.00 03/04/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956081
Principal investigator 1 ModernaTX, Inc. $1,720.00 03/04/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150736
Principal investigator 1 SANOFI PASTEUR INC. $45,565.56 03/04/2024 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700242
Principal investigator 1 GlaxoSmithKline, LLC. $3,308.04 03/01/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127530918
Principal investigator 1 Janssen Research & Development, LLC $1,347.00 03/01/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956127
Principal investigator 1 ModernaTX, Inc. $955.00 03/01/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150734
Principal investigator 1 Janssen Research & Development, LLC $6,185.00 02/29/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956123
Principal investigator 1 ModernaTX, Inc. $52,542.60 02/28/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150714
Principal investigator 1 ModernaTX, Inc. $103,797.40 02/28/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150726
Recipient SANOFI PASTEUR INC. $41.68 02/28/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699646
Recipient SANOFI PASTEUR INC. $78.00 02/28/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699648
Recipient SANOFI PASTEUR INC. $53.00 02/28/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699650
Recipient SANOFI PASTEUR INC. $9.27 02/28/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699652
Principal investigator 1 Janssen Research & Development, LLC $13,236.00 02/27/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956105
Principal investigator 1 Novavax Inc $100.00 02/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374158
Principal investigator 1 Novavax Inc $12,401.10 02/27/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376335
Recipient SANOFI PASTEUR INC. $260.62 02/27/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699632
Recipient SANOFI PASTEUR INC. $319.00 02/27/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699634
Recipient SANOFI PASTEUR INC. $125.00 02/27/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699636
Recipient SANOFI PASTEUR INC. $37.00 02/27/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699638
Recipient SANOFI PASTEUR INC. $73.00 02/27/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699640
Recipient SANOFI PASTEUR INC. $37.00 02/27/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699642
Recipient SANOFI PASTEUR INC. $160.00 02/27/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699644
Recipient SANOFI PASTEUR INC. $48.00 02/27/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699654
Recipient SANOFI PASTEUR INC. $88.59 02/27/2024 Covered Recipient Physician A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1128699656
Principal investigator 1 Boehringer Ingelheim International GmbH $7,844.82 02/26/2024 Non-covered Recipient Entity
Accel Research Sites Deland
MRD/PoCP study in NFLD (12 wks) No dispute reported 06/30/2026 1101069859
Principal investigator 1 GlaxoSmithKline, LLC. $2,650.00 02/26/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526656
Principal investigator 1 GlaxoSmithKline, LLC. $12,000.00 02/26/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526658
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 02/26/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530898
Principal investigator 1 GlaxoSmithKline, LLC. $1,650.00 02/26/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530900
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 02/26/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127530980
Principal investigator 1 Janssen Research & Development, LLC $106.00 02/26/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956155
Principal investigator 1 ModernaTX, Inc. $1,766.61 02/26/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150716
Principal investigator 1 Novo Nordisk AS $2,302.53 02/23/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096686805
Principal investigator 1 Novo Nordisk AS $321.50 02/23/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096709336
Principal investigator 1 Janssen Research & Development, LLC $1,042.00 02/22/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956077
Principal investigator 1 Janssen Research & Development, LLC $983.00 02/22/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956089
Principal investigator 1 Janssen Research & Development, LLC $612.00 02/22/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956183
Principal investigator 1 Janssen Research & Development, LLC $778.00 02/22/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956191
Principal investigator 1 ModernaTX, Inc. $33.50 02/20/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147178674
Principal investigator 1 SANOFI PASTEUR INC. $100.00 02/19/2024 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128700236
Principal investigator 1 Eli Lilly and Company $20,100.13 02/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137370064
Principal investigator 1 ModernaTX, Inc. $470.40 02/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150724
Principal investigator 1 Novavax Inc $75.00 02/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374156
Principal investigator 1 Novavax Inc $50.00 02/15/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376887
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,712.80 02/14/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1110838538
Principal investigator 1 Janssen Research & Development, LLC $500.00 02/14/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956189
Principal investigator 1 ModernaTX, Inc. $110,888.80 02/14/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150470
Principal investigator 1 SANOFI PASTEUR INC. $500.00 02/12/2024 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128700238
Principal investigator 1 SANOFI PASTEUR INC. $600.00 02/12/2024 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700246
Principal investigator 1 SANOFI PASTEUR INC. $38,044.62 02/12/2024 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700252
Principal investigator 1 Eli Lilly and Company $90,632.18 02/09/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1137370062
Principal investigator 1 GlaxoSmithKline, LLC. $1,191.53 02/09/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127530926
Principal investigator 1 ModernaTX, Inc. $29,268.54 02/09/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150712
Principal investigator 1 ModernaTX, Inc. $26,467.92 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150710
Principal investigator 1 Novavax Inc $12,000.00 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375215
Principal investigator 1 Novavax Inc $800.00 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375219
Principal investigator 1 Novavax Inc $500.00 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375221
Principal investigator 1 Novavax Inc $1,050.00 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375741
Principal investigator 1 Novavax Inc $400.00 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376329
Principal investigator 1 Novavax Inc $25.00 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376331
Principal investigator 1 Novavax Inc $316.92 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376333
Principal investigator 1 Novavax Inc $400.00 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376885
Principal investigator 1 Novavax Inc $340.00 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377427
Principal investigator 1 Novavax Inc $800.00 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377429
Principal investigator 1 Novavax Inc $39,813.43 02/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123378005
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,143.28 02/07/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1110839546
Principal investigator 1 Janssen Pharmaceuticals, Inc $108.00 02/07/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1078938504
Principal investigator 1 ModernaTX, Inc. $2,018.28 02/07/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150708
Principal investigator 1 ModernaTX, Inc. $637.56 02/05/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150706
Principal investigator 1 GlaxoSmithKline, LLC. $2,933.22 02/02/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127526650
Principal investigator 1 ModernaTX, Inc. $847.28 01/29/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150670
Principal investigator 1 ModernaTX, Inc. $7,532.00 01/29/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150686
Principal investigator 1 Amgen Inc. $21,540.72 01/26/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AMG 451 DDI/Atopic Dermatitis No dispute reported 06/30/2026 1096308037
Principal investigator 1 Janssen Research & Development, LLC $10,143.00 01/26/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956157
Principal investigator 1 Eli Lilly and Company $4,707.51 01/25/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS No dispute reported 06/30/2026 1137368738
Principal investigator 1 ModernaTX, Inc. $2,156.88 01/25/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150668
Principal investigator 1 GlaxoSmithKline, LLC. $1,825.29 01/24/2024 Non-covered Recipient Entity
UNIVERSITY OF CLINICAL DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127526646
Principal investigator 1 Janssen Research & Development, LLC $529.00 01/24/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956119
Principal investigator 1 Janssen Research & Development, LLC $78.00 01/24/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956169
Principal investigator 1 Janssen Research & Development, LLC $1,530.00 01/24/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956193
Principal investigator 1 ModernaTX, Inc. $100.00 01/24/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150666
Principal investigator 1 ModernaTX, Inc. $2,543.16 01/24/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150684
Principal investigator 1 Novo Nordisk AS $1,468.10 01/24/2024 Non-covered Recipient Entity
ACCEL RESEARCH SITES
NN9536-7545 No dispute reported 06/30/2026 1096696008
Principal investigator 1 GlaxoSmithKline, LLC. $417.94 01/22/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127530982
Principal investigator 1 ModernaTX, Inc. $6,059.81 01/19/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150460
Principal investigator 1 Janssen Research & Development, LLC $7,485.00 01/18/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956159
Principal investigator 1 ModernaTX, Inc. $29,406.30 01/18/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150664
Principal investigator 1 SANOFI PASTEUR INC. $600.00 01/18/2024 Non-covered Recipient Entity
University Clinical Research,LLC DBA Avail Clinical Research,LLC
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128700244
Principal investigator 1 ModernaTX, Inc. $1,683.00 01/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147150662
Principal investigator 1 ModernaTX, Inc. $2,766.61 01/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147150672
Principal investigator 1 ModernaTX, Inc. $6,732.60 01/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150682
Principal investigator 1 Janssen Research & Development, LLC $3,846.00 01/10/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956091
Principal investigator 1 Janssen Research & Development, LLC $1,510.00 01/10/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956153
Principal investigator 1 Janssen Research & Development, LLC $507.00 01/10/2024 Non-covered Recipient Entity
Univ Clinic Rsrch - Deland, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078956167
Principal investigator 1 ModernaTX, Inc. $2,725.80 01/10/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150680
Principal investigator 1 ModernaTX, Inc. $9,198.00 01/08/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150678
Principal investigator 1 ModernaTX, Inc. $400.00 01/05/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150456
Principal investigator 1 ModernaTX, Inc. $800.00 01/05/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147150458
Principal investigator 1 ModernaTX, Inc. $8,928.60 01/04/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147150674
Principal investigator 1 GlaxoSmithKline, LLC. $2,904.62 01/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH-DELAND LLC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1127526664
Principal investigator 1 ModernaTX, Inc. $500.00 01/03/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147150462